Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium.
The intestinal epithelium forms a physical barrier to limit access of enteric microbes to the host and contributes to innate host defense by producing effector molecules against luminal microbes. To further define the role of the intestinal epithelium in antimicrobial host defense, we analyzed the expression, regulation, and production of two antimicrobial peptides, human defensins hBD-1 and hBD-2, by human intestinal epithelial cells in vitro and in vivo. The human colon epithelial cell lines HT-29 and Caco-2 constitutively express hBD-1 mRNA and protein but not hBD-2. However, hBD-2 expression is rapidly induced by IL-1alpha stimulation or infection of those cells with enteroinvasive bacteria. Moreover, hBD-2 functions as a NF-kappaB target gene in the intestinal epithelium as blocking NF-kappaB activation inhibits the up-regulated expression of hBD-2 in response to IL-1alpha stimulation or bacterial infection. Caco-2 cells produce two hBD-1 isoforms and a hBD-2 peptide larger in size than previously described hBD-2 isoforms. Paralleling the in vitro findings, human fetal intestinal xenografts constitutively express hBD-1, but not hBD-2, and hBD-2 expression, but not hBD-1, is up-regulated in xenografts infected intraluminally with Salmonella. hBD-1 is expressed by the epithelium of normal human colon and small intestine, with a similar pattern of expression in inflamed colon. In contrast, there is little hBD-2 expression by the epithelium of normal colon, but abundant hBD-2 expression by the epithelium of inflamed colon. hBD-1 and hBD-2 may be integral components of epithelial innate immunity in the intestine, with each occupying a distinct functional niche in intestinal mucosal defense.
O'Neil
D A
DA
Laboratory of Mucosal Immunology, Department of Medicine, University of California at San Diego, La Jolla 92093, USA.
Porter
E M
EM
Elewaut
D
D
Anderson
G M
GM
Eckmann
L
L
Ganz
T
T
Kagnoff
M F
MF
D000900:Anti-Bacterial Agents / Q000378:metabolism*; D018938:Caco-2 Cells / Q000378:metabolism; D003093:Colitis, Ulcerative / Q000378:metabolism / Q000473:pathology; D003106:Colon / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D023082:Defensins; D005786:Gene Expression Regulation / Q000276:immunology; D019073:HT29 Cells; D006801:Humans; D007375:Interleukin-1 / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism; D010452:Peptide Biosynthesis / Q000276:immunology; D014176:Protein Biosynthesis; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000096:biosynthesis; D012480:Salmonella Infections / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D014183:Transplantation, Heterologous / Q000276:immunology; D023083:beta-Defensins
D000900:Anti-Bacterial Agents; C406407:DEFB1 protein, human; C106641:DEFB4A protein, human; D023082:Defensins; D007375:Interleukin-1; D016328:NF-kappa B; D011506:Proteins; D012333:RNA, Messenger; D023083:beta-Defensins